Metropolis Healthcare Q1 FY27: Revenue Rs 450 Cr, EBITDA margin at 25.2%

Metropolis Healthcare Ltd has kicked off FY27 with double‑digit growth and margin expansion, as outlined in its investor and analyst meet presentation dated 27 August 2026.

Q1 FY27 headline numbers

According to the FY27 outlook slide in the investor presentation (page 22):

• Revenue for Q1 FY27 was Rs 450 crore, up 17% year‑on‑year.
• EBITDA margin for Q1 FY27 stood at 25.2%, an expansion of 210 basis points YoY.

The presentation does not disclose absolute EBITDA or profit after tax figures for Q1 FY27, nor the prior‑year quarter’s revenue or EBITDA in rupee terms. Only the percentage revenue growth and margin expansion are provided.

The company has maintained its full‑year FY27 revenue growth guidance at 14–15%, explicitly stating that this assumes no price increase (page 22). Q1’s 17% revenue growth is described as being “ahead of the trajectory” implied by that guidance.

Metropolis is also guiding for an EBITDA margin improvement of 100–150 bps for FY27 versus the prior year (page 22). The Q1 FY27 EBITDA margin of 25.2% is positioned as a step towards a medium‑term margin ambition of 27–28% (page 24).

Volume and mix drivers in Q1 FY27

The company attributes the strong start to FY27 primarily to volume and mix rather than pricing:

• Patient volume grew 10% and test volume grew 11% in Q1 FY27 (page 26), underpinning the 17% revenue growth.
• B2C led the quarter with 18% growth, while rural centres grew 36% (page 22).
• Specialty revenue grew 17% in Q1 FY27, and the genomics portfolio doubled following the Core acquisition (page 16 and page 18).
• Tier III town revenue rose about 25%, compared with 14% in Tier II and 11% in Tier I cities (page 22), highlighting faster growth from smaller markets.
• The company added 295 service points and 36 new tests during the quarter (page 22).

Management reiterates that growth is volume‑led, with price increases held in reserve as a lever rather than a current driver (page 26).

Strategic context and three‑year plan

Beyond the quarter, the presentation lays out a three‑year roadmap built around five growth engines: network expansion, TruHealth wellness and adjacencies, specialty tests (including genomics), technology, and inorganic acquisitions (page 12).

Key elements include:

• Network and channels: Metropolis operates in 750+ towns with 209 laboratories and over 5,000 collection centres, generating FY26 revenue of Rs 1,646 crore (page 3). The plan is to scale to ~1,000 own centres over three years and increase the centre‑to‑lab ratio from 24:1 to ~35:1 (page 13 and page 14).
• B2C/B2B mix: B2C contributes 57% and B2B 43% of revenue, with 26% of revenue from Tier 3 and smaller towns (page 14). The company aims to push TruHealth wellness packages towards 25% of revenue over three years, up from 18% currently (page 15).
• Specialty and genomics: Specialty tests currently account for 40% of revenue in Q1 FY27, with a target of ~45% over three years (page 16). The menu includes 2,200+ specialty tests, with 347 tests added in FY26 and 36 in Q1 FY27 (page 5 and page 16). Genomics is described as the fastest‑growing segment within specialty, with the portfolio having doubled over the past year and supported by two CAP‑accredited genomics labs in Gurgaon and Mumbai (page 17).
• TruHealth and adjacencies: TruHealth preventive and wellness bundles have an average ticket size of about Rs 2,500 and are said to be “in line” with company‑level margins (page 15). The company highlights ~40% growth in radiology‑integrated and premium packages (page 15).

Margin and capital efficiency agenda

Metropolis outlines five levers to move EBITDA margin from 24.4% in FY26 towards 27–28% over the medium term (page 24):

1. Specialty & digital mix: Premiumisation via higher specialty, genomics and digital share.
2. Lab & centre density: Improving centre‑to‑lab ratio to 35:1.
3. Platform standardisation: Common menu, equipment and reagents, plus vendor consolidation.
4. Cost efficiency & automation: AI‑led re‑engineering and lab automation.
5. Core margin convergence: Targeting 20%+ EBITDA margin for the acquired Core business by year three.

On the balance sheet side, the company is targeting single‑digit working capital days, keeping capex at about 4% of revenue, and focusing on ROCE improvement and a regular dividend payout (page 25).

The management summarises its approach as: “Growth is volume‑led, margin comes from utilisation, and capital now compounds” (page 26), with Q1 FY27 performance presented as consistent with that framework.